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aylored prevention of postoperative endoscopic
ecurrence in Crohn’s disease: new data for an old
roblemrevenc¸ão individualizada de recorrência endoscópica pós-operatória
a doenc¸a de Crohn: novos dados para um antigo problemarohn’s disease (CD) is a recurrent entity, and is not cur-
ble even with surgery.1 Despite the ultimate advances in
ts management, including new diagnostic tools (such as
ecal calprotectin and enterography with magnetic resonance
maging), as well as efﬁcacious therapeutic agents (such as
iological drugs), surgery still plays a signiﬁcant role in the
D treatment algorithms.1 Populational studies demonstrated
hat after 20 years of diagnosis, up to 80% of the patients may
eed at least one intestinal resectionduring thenatural course
f the disease.2 Recurrence of CD is common, and usually
ccurs near the anastomosis of the previous operation.3
There are several types of recurrence in CD. Histologic
ecurrence is often the ﬁrst to occur, and can be observed
eeks after an operation that included resection. Endoscopic
ecurrence usually occurs around one year after the surgical
esections, and precedes clinical (symptomatic) and surgical
ecurrences.3 Therefore, postoperative endoscopic recurrence
PER) is one of the initial signs of future symptoms, future need
or multiple operations and disability. The occurrence of PER
nd its possible causes had been studied for decades, since
he pivotal study by Rutgeerts et al., in 1990.4
Several strategies had been described in the prevention of
ER, as well as its management once it is clearly detected.
tratiﬁcation of the patients regarding their risk for recur-
ence, according to several risk factors such as smoking,
revious resections, perforating CD and mioenteric plexitis,
an help physicians to deﬁne the best drug to be used in
ach individual case.3 Traditionally, patients with high risk
or recurrence (with one or more of the risk factors previ-
usly stated) are managed with more powerful drugs, such
s immunomodulators and TNF-alpha inhibitors, in order to
educe PER rates. Patients with low risk for recurrence, usuallythosewith the ﬁrst resection and luminal disease, can beman-
aged with antibiotics and close follow-up, even without any
treatment for some periods.3
The difﬁculties thatwe face as physicians, aremostly based
on the uncertain course of the disease after an operation. We
must avoid overtreatment (treating patients with biological
agentswithout a clear need for this therapy), due to the risks of
adverse events, as well as important cost-efﬁcacy issues. On
the other hand, we must also avoid undertreatment, which
means to ignore risk factors and simply treat patients with
worse prognostic factors with drugs of uncertain efﬁcacy. In
summary, we cannot treat all patients with a single strat-
egy, and data regarding comparison of different algorithms are
scarce.
In February 2014, during the European Crohn’s and Colitis
(ECCO) congress, in Denmark, the ﬁnal results of the POCER
trial were presented.5 This was the ﬁrst prospective multi-
center trial that compared the rates of PER after two different
strategies of prevention of its occurrence. This study included
patientswith “curative” ileocecal resection, without any resid-
ual CD, that were followed for 18 months. In one arm of the
study, patients were treated according to their risk factors
in isolation, with the best drug regimen at hand, and had a
colonoscopy after 18 months to check the rates of PER. In the
other arm, patients were initially treated according to their
risk factors, but a colonoscopy after 6 months of the resection
could deﬁne the patients already with PER, and escalate them
to the next therapeutic agent, in order to optimize PER reduc-
tion at the end of the 18 months period of the study. In
summary, the treat-to-target strategy (aiming mucosal heal-
ing, with an interventional colonoscopy) was tested against
regular treatment.
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The results of the POCER trial (with 174 patients) demon-
strated that patientswho had their therapeutic decision based
on a colonoscopy 6 months after the operation (active care
arm), had lower PER rates (49%) after 18 months than patients
that were treated according to the best drug regimen (67% -
standard care arm), with p=0.028.5
The conclusions of this important trial, with a high level
of evidence, were that treating according to the risk of recur-
rence, with early colonoscopy and treatment step-up for
recurrence, was superior to optimal drug therapy alone in
preventing post-operative CD recurrence. Another important
lesson from this study, was that selective immunosuppres-
sion (with azathioprine and Adalimumab, when needed),
with colonoscopy-based adjustment, rather than its use in
all high risk patients, lead to effective disease control in
the majority of patients. Tayloring the treatment demon-
strated better results than treating every patient with a ﬁxed
strategy.
In an era where biological agents are fully available world-
wide, the selection of the proper use of these drugs for the
proper patients is essential to avoid overtreatment. Therefore,
the aphorism that every patient submitted to an operation
needs to escalate therapy to the biological level, is not fully
accepted. Although not yet clear in the majority of Inﬂamma-
tory Bowel Diseases guidelines, the strategy of a colonoscopy
6months after an ileocecal resection to detect PER seems to be
the best strategy to manage CD patients after surgery to date.
Fecal calprotectin trials are also needed in order to optimize
the timing for the ﬁrst colonoscopy after surgery. Endoscopic
assessment seems to be essential for amore precise deﬁnition
of the best drug for our patients. The POCER trial demonstrated
the best evidence in the management of PER in the last years.
It brought good and new data to face the old problem of recur-
rence.
Asweknow,CD is a lifelongdisease. Therefore, studieswith
longer follow-up periods are still needed, to check the beneﬁts014;34(2):65–66
of the strategy demonstrated in the POCER trial in the long
term. There are still lots of questions to be determined in the
management of PER. We hope that this old problem can have
better and new solutions in the years to come.
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